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A top priority in pre-eclampsia research: development of a 
reliable and inexpensive urinary screening test
Pre-eclampsia is a leading cause of maternal and perinatal 
mortality and morbidity worldwide, with an estimated 
60 000 pre-eclampsia-related maternal deaths per year.1 
This complication of human pregnancy has increased 
in incidence in the past decade and can be avoided by 
timely and effective care (secondary prevention).2 Pre-
eclampsia is defined by new hypertension and organ 
damage (mainly involving the kidney and sometimes the 
liver) that can evolve into eclamptic seizures, maternal 
stroke, and abruptio placentae. Despite extensive 
research by obstetricians, paediatricians, immunologists, 
cardiologists, epidemiologists, and anthropologists, pre-
eclampsia remains a complex and heterogenous disorder 
of elusive pathophysiology.
We formed the International Group of Reproductive 
Immuno logy, Immunological Tolerance and 
Immunology of Preeclampsia in 1998, aiming to study 
the causes and address key gaps in the knowledge of 
pre-eclampsia. Our consensus is that the condition 
arises because of altered placental development as 
demonstrated by impaired secretion of pro-angiogenic 
placental growth factor (PlGF), which leads to placental 
release into the maternal circulation of angiogenic 
factors, including soluble endoglin (sEng) and soluble 
fms-like tyrosine kinase (sFlt). These factors are strongly 
correlated with development of maternal syndrome 
(hypertension, proteinuria, and organ damage) and 
are shown to increase at or before onset of clinical 
symptoms.3,4
In The Lancet, Emmanuel Bujold and colleagues5 
commented on a controlled trial from the PARROT group 
describing testing of pro-angiogenic placental growth 
factor to optimise pre-eclampsia diagnosis.4 Bujold and 
colleagues5 highlighted that this test was used in large, 
high-resource maternity units; however, the investigators 
suggested to evaluate the additional role of ultrasound in 
future research to improve clinical outcomes. Since the 
highest incidence of pre-eclampsia occurs in low-income 
and middle-income countries that rely on basic means,1 
it would be most appropriate to focus on developing 
an inexpensive, easy-to-administer (with minimal 
discomfort), reliable, and validated test. On the basis of 
research progress to date, several research priorities were 
agreed during a workshop on Reunion Island, France, in 
December 2018, which involved 22 participants recruited 
from research groups worldwide. The first and paramount 
priority is to achieve a reliable and inexpensive screening 
test, which represents the main issue to be addressed: 
optimising clinical assistance to prevent maternal and 
fetal morbidity. Urinary tests remain the best inexpensive 
option that could be administered in low-resource 
settings and even rural areas in low-income countries. 
Therefore, patients might be identified and referred to 
specific clinical pathways offering increased surveillance 
to avoid medical interventions being ineffective because 
of late presentation.
Various candidate biomarkers and approaches exist, but 
the most exciting and tractable options as urinary tests 
are detection of urinary misfolded proteins using azo-
dye Congo Red,6 adipsin,7 and inositol phosphoglycans 
P-type.8 Kara Rood and colleagues6 did a prospective 
study in a university setting in Ohio, USA, using a semi-
quantitative analysis based on a specifically developed 
paper-based urine test kit. Urinary adipsin is another valid 
candidate that showed high sensitivity (90%) and good 
specificity (78%) in a longitudinal study in a university 
hospital in China.7 Like the PARROT study,4 these two 
studies focused on the potential of the test to optimise 
diagnosis, whereas screening potential was minimally 
investigated. A longitudinal study in a low-income 
country9 also identified inositol phosphoglycans P-type as 
one of several metabolic molecules in maternal urine that 
show identification of women destined to develop pre-
eclampsia 3–4 weeks before onset of clinical symptoms 
is possible. Other emerging urine biomarkers that 
showed positive per formances are neutrophil gelatinase-
associated lipocalin and complement biomarkers, such 
as C5a and C5b-9.10 Detection and quantification of 
inositol phosphoglycans P-type, neutrophil gelatinase-
associated lipocalin, and complement biomarkers are 
achieved via ELISA; therefore, development of a simple 
method on the basis of urine strips or similar should be 
feasible. Clinical studies including urinary routine testing 
during every antenatal visit would test improvement of 
early diagnosis compared with routine antenatal care and 
capacity for tertiary prevention.2 Given the availability 
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of several candidate urinary biomarkers, we propose 
that diagnostic companies should allocate resources 
towards development of a low-cost urine test that is 
specific for pre-eclampsia diagnosis, as this test would 
have substantial benefits, particularly in low-income and 
middle-income countries where resources for expensive 
blood tests might not be available.
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